Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19363724 | 0.83 | — | — | |
| SCHEMBL18737487 | 0.82 | TSHR (0.41) | MAPK1 | |
| SCHEMBL9005354 | 0.78 | HCAR2 (0.48) | — | |
| SCHEMBL9005303 | 0.75 | MAPT (0.49) | — | |
| SCHEMBL9697280 | 0.74 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL9697274 | 0.74 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL461154 | 0.73 | — | — | |
| SCHEMBL13039799 | 0.73 | — | — | |
| SCHEMBL1161835 | 0.73 | — | — | |
| SCHEMBL25276069 | 0.71 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20150087628-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-03-26 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | MAPK1 199/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | MAPK1 1129/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | MAPK1 333/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | MAPK1 199/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | MAPK1 1129/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | MAPK1 820/4885 |
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | MAPK1 1129/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | MAPK1 1129/4885 |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | AR, LHCGR, FSHR | MAPK1 3210/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | MAPK1 199/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | MAPK1 199/4885 |
| US-20150087628-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | MAPK1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.